Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Stockholders' Equity (Deficit)

v3.20.2
Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Balance (in shares) at Dec. 31, 2018   4,198      
Beginning balance at Dec. 31, 2018 $ 2,728 $ 4 $ 173,962 $ (92) $ (171,146)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net Income (Loss) (6,551)       (6,551)
Issuance of common stock under:          
Equity financing, net (in shares)   291      
Equity financing, net 7,305   7,305    
Equipois sales earn-outs (in shares)   1      
Equipois sales earn-out 22   22    
Equity incentive plan (in shares)   3      
Equity incentive plan 55   55    
Matching contribution to 401(k) plan (in shares)   9      
Matching contribution to 401(k) plan 191   191    
Stock-based compensation expense 636   636    
Foreign currency translation adjustments 148     148  
Balance (in shares) at Mar. 31, 2019   4,502      
Ending balance at Mar. 31, 2019 4,534 $ 4 182,171 56 (177,697)
Balance (in shares) at Dec. 31, 2018   4,198      
Beginning balance at Dec. 31, 2018 2,728 $ 4 173,962 (92) (171,146)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net Income (Loss) (9,411)        
Balance (in shares) at Sep. 30, 2019   4,996      
Ending balance at Sep. 30, 2019 6,421 $ 4 186,700 274 (180,557)
Balance (in shares) at Mar. 31, 2019   4,502      
Beginning balance at Mar. 31, 2019 4,534 $ 4 182,171 56 (177,697)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net Income (Loss) (3,066)       (3,066)
Issuance of common stock under:          
Equity financing, net (in shares)   444      
Equity financing, net 2,393   2,393    
Equipois sales earn-outs (in shares)   9      
Equipois sales earn-out 173   173    
Equity incentive plan (in shares)   37      
Equity incentive plan 919   919    
Stock-based compensation expense 557   557    
Foreign currency translation adjustments (106)     (106)  
Balance (in shares) at Jun. 30, 2019   4,992      
Ending balance at Jun. 30, 2019 5,404 $ 4 186,213 (50) (180,763)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net Income (Loss) 206       206
Issuance of common stock under:          
Equity incentive plan (in shares)   4      
Stock-based compensation expense 487   487    
Foreign currency translation adjustments 324     324  
Balance (in shares) at Sep. 30, 2019   4,996      
Ending balance at Sep. 30, 2019 6,421 $ 4 186,700 274 (180,557)
Balance (in shares) at Dec. 31, 2019   5,795      
Beginning balance at Dec. 31, 2019 6,797 $ 6 190,019 50 (183,278)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net Income (Loss) (2,534)       (2,534)
Issuance of common stock under:          
Matching contribution to 401(k) plan (in shares)   26      
Matching contribution to 401(k) plan 155   155    
In lieu of cash compensation (in shares)   9      
In lieu of cash compensation 50   50    
Shares issued as a result of rounding due to reverse-stock split (in shares)   13      
Stock-based compensation expense 587   587    
Foreign currency translation adjustments 173     173  
Balance (in shares) at Mar. 31, 2020   5,843      
Ending balance at Mar. 31, 2020 5,228 $ 6 190,811 223 (185,812)
Balance (in shares) at Dec. 31, 2019   5,795      
Beginning balance at Dec. 31, 2019 6,797 $ 6 190,019 50 (183,278)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net Income (Loss) (11,849)        
Balance (in shares) at Sep. 30, 2020   8,316      
Ending balance at Sep. 30, 2020 8,401 $ 8 203,905 (385) (195,127)
Balance (in shares) at Mar. 31, 2020   5,843      
Beginning balance at Mar. 31, 2020 5,228 $ 6 190,811 223 (185,812)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net Income (Loss) (11,767)       (11,767)
Issuance of common stock under:          
Equity financing, net (in shares)   1,748      
Equity financing, net 7,082 $ 2 7,080    
Exercise of warrants (in shares)   223      
Exercise of warrants 1,436   1,436    
Issuance of warrants (2,322)   (2,322)    
Stock-based compensation expense 508   508    
Foreign currency translation adjustments (193)     (193)  
Balance (in shares) at Jun. 30, 2020   7,814      
Ending balance at Jun. 30, 2020 (28) $ 8 197,513 30 (197,579)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net Income (Loss) 2,452       2,452
Issuance of common stock under:          
Equity incentive plan (in shares)   2      
Exercise of warrants (in shares)   500      
Exercise of warrants 5,875   5,875    
Stock-based compensation expense 517   517    
Foreign currency translation adjustments (415)     (415)  
Balance (in shares) at Sep. 30, 2020   8,316      
Ending balance at Sep. 30, 2020 $ 8,401 $ 8 $ 203,905 $ (385) $ (195,127)